Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 5/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 4/20 | 1.00 |
| ▸ | EGFR | P00533 | 3/20 | 1.00 |
| ▸ | KIT | P10721 | 2/20 | 1.00 |
| ▸ | NEK2 | P51955 | 2/20 | 1.00 |
| ▸ | MELK | Q14680 | 2/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 14/20 | 0.87 |
| ▸ | PRKAA2 | P54646 | 13/20 | 0.87 |
| ▸ | FLT3 | P36888 | 4/20 | 0.81 |
| ▸ | PLK4 | O00444 | 2/20 | 0.81 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.81 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.81 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.81 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.81 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.81 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.81 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.81 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.81 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Su-11652 SCHEMBL2114096 | 1.00 | KDR (1.00) | KDRPDGFRBFGFR1EGFRKIT | |
| Su-11652 SCHEMBL21067494 | 1.00 | KDR (1.00) | KDRPDGFRBFGFR1EGFRKIT | |
| Su-11652 SCHEMBL2212420 | 1.00 | KDR (1.00) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL29857040 | 0.93 | PRKAA1 (1.00) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL31672439 | 0.91 | KDR (0.84) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL15202704 | 0.91 | KDR (0.84) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL2113942 | 0.91 | KDR (0.84) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL13755223 | 0.91 | KDR (0.84) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL22486002 | 0.90 | KDR (0.82) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL18651190 | 0.90 | KDR (0.85) | KDRPDGFRBFGFR1EGFRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355581-A1 | METHODS OF TREATMENT FOR MELANOMA | The Board of Regents of the Unversity of Texas System (US) | 2023-11-09 | — | — | US | claimed |
| CN-114585356-A | Methods of preventing or treating diseases associated with VEGFR and/or VEGF inhibition | 上海岸阔医药科技有限公司 | 2022-06-03 | — | — | CN | claimed |
| WO-2022006512-A9 | METHODS OF TREATMENT FOR MELANOMA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-02-24 | — | — | WO | claimed |
| CN-114028568-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| CN-113975264-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-01-28 | — | — | CN | claimed |
| CN-122055160-A | Methods of treating seizure activity | 神经元治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4599890-A2 | SUNITINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2025-08-13 | — | — | EP | disclosed |
| US-20250170090-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR DISORDER ASSOCIATED WITH ANTINEOPLASTIC AGENT | ONQUALITY PHARMACEUTICALS CHINA LTD (CN) | 2025-05-29 | — | — | US | disclosed |
| WO-2025075929-A1 | METHODS OF TREATING SEIZURE ACTIVITY | NEURONA THERAPEUTICS INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| EP-4470565-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR DISORDER ASSOCIATED WITH ANTINEOPLASTIC AGENT | OnQuality Pharmaceuticals China Ltd. (CN) | 2024-12-04 | — | — | EP | disclosed |
| US-20240366627-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-11-07 | — | — | US | disclosed |
| CN-118742325-A | Methods for preventing or treating diseases or conditions associated with antineoplastic agents | 上海岸阔医药科技有限公司 | 2024-10-01 | — | — | CN | disclosed |
| US-11426400-B2 | Methods of increasing satellite cell proliferation with vorinostat or bosutinib | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-08-30 | — | — | US | disclosed |
| CN-114585356-A | Methods of preventing or treating diseases associated with VEGFR and/or VEGF inhibition | 上海岸阔医药科技有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20220087987-A1 | A METHOD FOR TREATING SWI/SNF COMPLEX-DEFICIENT CANCERS COMPRISING GLUTATHIONE (GSH) METABOLIC PATHWAY INHIBITOR | NATIONAL CANCER CENTER (JP) | 2022-03-24 | — | — | US | disclosed |
| WO-2022006512-A9 | METHODS OF TREATMENT FOR MELANOMA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022006512-A9 | METHODS OF TREATMENT FOR MELANOMA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-02-24 | — | — | WO | disclosed |
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-02-24 | — | — | US | disclosed |
| CN-114028568-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
| CN-113975264-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | KDR 2116/4885PDGFRB 197/4885FGFR1 475/4885 |
| US-20250170090-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR DISORDER ASSOCIATED WITH ANTINEOPLASTIC AGENT | VHL, SLC10A1, NNMT | KDR 4883/4885PDGFRB 4796/4885FGFR1 4524/4885 |
| US-20240366627-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | KDR 2116/4885PDGFRB 197/4885FGFR1 475/4885 |
| US-11426400-B2 | Methods of increasing satellite cell proliferation with vorinostat or bosutinib | MKI67, CDK4, CDKN1A | KDR 1684/4885PDGFRB 510/4885FGFR1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.